98%
921
2 minutes
20
Background: Raphe-type bicuspid aortic valve (BAV) is a potential hostile scenario in trans-catheter aortic valve replacement (TAVR) due to pronounced calcium burden, possibly associated with tapered valve configuration. Trans-Catheter heart valve (THV) sizing strategy (annular vs. supra-annular) is controversial in this valve subtype.
Objectives: To describe the phenotypical characteristics of severe, tapered, raphe-type, BAV stenosis undergoing TAVR and to explore safety and efficacy of modern-generation THVs, analysing the impact of annular and supra-annular sizing strategies on short- and mid-terms outcomes.
Methods: This is a retrospective, multicenter registry enrolling consecutive stenotic Sievers type 1 BAV treated with TAVR. Study population was divided into tapered and non-tapered configuration according to MSCT analysis. Matched comparison between annular and supra-annular sizing groups was performed in tapered population.
Results: From January 2016 to June 2023, 897 patients were enrolled. Of them, 696 patients displayed a tapered configuration. Of those, 510 received a THV according to annular sizing. After propensity score matching 186 matched pairs were selected. Technical success (96.2 % vs 94.1 %, OR 1.61 [0.61-4.24], p = 0.34), 30-day device success (83.6 % in both groups, OR 1.42 [0.78-2.57], p = 0.25) and 30-day early safety (71.8 % vs 70.5 %, OR 1.07 [0.68-1.68], p = 0.78) were similar between the annular and supra-annular sizing groups; a higher post-TAVR gradient was observed in supra-annular group, although it was only 2 mmHg mean. At mid-term follow-up, the rate of clinical efficacy was 84.7 %.
Conclusions: TAVR with modern-generation devices is safe and effective for tapered raphe-type BAV, showing comparable results for annular and supra-annular sizing strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2024.132569 | DOI Listing |
Catheter Cardiovasc Interv
September 2025
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Background: With transcatheter aortic valve implantation (TAVI) now extending to lower-risk and younger patients, optimizing procedural and hemodynamic outcomes is critical. The Myval Octacor, a new balloon-expandable valve (BEV), was developed to improve outcomes by reducing paravalvular regurgitation (PVL), minimizing pacemaker implantation (PPI) rates, and enhancing hemodynamic performance. However, limited data are available comparing Myval Octacor to contemporary self-expanding supra-annular valves (SEVs) Evolut PRO/PRO+ and Acurate Neo2.
View Article and Find Full Text PDFJ Clin Med
August 2025
Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine & Health, Technical University of Munich, 80636 Munich, Germany.
The novel Navitor intra-annular self-expandable transcatheter aortic valve prosthesis is designed to improve coronary access, reduce paravalvular leaks, and enhance hemodynamic performance. Comparative data with the established Evolut platform (R, Pro, FX) are still lacking. This study aimed to evaluate the short-term clinical outcomes of Navitor (NAV) versus Evolut transcatheter heart valves.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
August 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Background: Ensuring coronary access is essential for lifetime management after transcatheter aortic valve replacement (TAVR). However, the data on coronary alignment using the latest supra-annular (SA) and intra-annular (IA) self-expandable valves (SEV) are limited.
Aims: This study evaluated coronary alignment after TAVR using SA-SEV and IA-SEV using post-procedural CT images.
JACC Cardiovasc Interv
July 2025
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
JACC Cardiovasc Interv
July 2025
Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Annular measurements traditionally guide transcatheter heart valve sizing in transcatheter aortic valve replacement (TAVR). Although supra-annular assessment has emerged as a crucial consideration, particularly in bicuspid aortic valve (BAV) cases, current measurement methods lack standardization and reproducibility.
Objectives: The aim of this study was to develop and validate a standardized multiplanar approach for transcatheter heart valve sizing integrating both annular and supra-annular measurements.